Major Shareholder Converts Preferred Stock, Backs Obsidian Merger with 26.5% Stake
GRTX has more than doubled off its 52-week low of $0.015 on light trading volume (0.2× avg).
Summary
Emerald Bioventures, holding 26.5% of Galera Therapeutics' common stock, converted a significant portion of its preferred shares and formally committed to supporting the pending merger with Obsidian Therapeutics.
Key Events · Ownership and Investor Activity · GRTX
-
Major Stock Conversion
Emerald Bioventures converted 37,158,187 shares of Series B Preferred Stock into common stock on April 7, 2026, following a partial mandatory conversion initiated by the Issuer.
-
Significant Ownership Stake
Following the conversion, Emerald Bioventures now beneficially owns 40,216,160 shares of common stock, representing 26.5% of the outstanding shares.
-
Merger Support Agreement
Emerald Bioventures formally committed to voting its 26.5% stake in favor of the pending merger with Obsidian Therapeutics, as part of a broader support agreement with other major shareholders, which was announced on April 14, 2026.
Analysis · GRTX · Life Sciences
This Schedule 13D filing reveals Emerald Bioventures, a significant investor, has converted over 37 million shares of Series B Preferred Stock into common stock, increasing its common stock ownership to 26.5%. This conversion, while dilutive, is a step in the company's capital structure adjustments. Crucially, Emerald Bioventures has also entered into a Stockholder Support Agreement, pledging its 26.5% stake to vote in favor of the definitive merger agreement with Obsidian Therapeutics, announced on April 14, 2026. This strong commitment from a major shareholder significantly de-risks the merger's approval, which is vital for Galera Therapeutics given its previously disclosed "going concern" warning.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GRTX was trading at $0.10 on OTC in the Life Sciences sector, with a market capitalization of approximately $16.4M. The 52-week trading range was $0.02 to $0.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.